

INDEX

Chapter	Section	Title	Page no.
1. Introduction.	1.1.	Cancer and its global impact.	1
	1.2.	Treatment of Cancer and barriers to drug delivery.	1
	1.3.	Brain tumours and its complications	2
	1.4.	Drug targeting in cancer with nanotechnology.	2
	1.5.	Diagnostic tools for cancer.	3
	1.5.1.	Magnetic resonance imaging in cancer (MRI).	3
	1.6.	Concept of Theranostics- A mixed approach of therapy and diagnosis.	3
	1.7.	Polymers used in theranostic applications.	4
	1.8.	Iron oxide based nanoparticles.	5
	1.9.	Anti angiogenic drugs in treatment of glioblastoma and challenges to delivery.	6
	1.10.	Aims, Objectives, Rationale and hypothesis.	7
	1.11.	Plan of work.	8
	1.12.	References	9
2. Literature Review.	2.1.	Epidemiology of CNS and brain tumours.	11
	2.2.	Role of molecular markers in glioma.	11
	2.2.1.	Isocitrate dehydrogenase (IDH).	11
	2.2.2.	O6-methylguanine-DNA methyltransferase methylation (MGMT).	12
	2.2.3.	1p and 19 q deletion.	12
	2.2.4.	p53 tumour protein	
	2.2.5.	Telomerase reverse transcriptase (TERT).	12
	2.2.6.	Alpha-thalassemia/mental retardation syndrome X-linked (ATRX).	13
	2.2.7.	H3K27 mutation.	13
	2.2.8.	RELA fusion and BRAF.	13
	2.3.	Glioblastoma multiforme: Most aggressive form of glioma.	14
	2.3.1.	Pathophysiology and Risk factors associated with Glioblastoma multiforme.	14
	2.3.2.	Magnetic resonance imaging (MRI).	15
	2.4.	Chemotherapy for glioma.	18
	2.5.	Drawbacks of conventional therapy for glioblastoma.	19
	2.6.	Lenalidomide-A novel anticancer drug.	20
	2.6.1.	Chemistry .	20
	2.6.2.	Pharmacokinetics.	21
2.6.3.	Mechanism of action.	21	

Chapter	Section	Title	Page no.
2. Literature Review.	2.7.	Use of Vascular endothelial growth factor inhibitors in glioma.	21
	2.8.	Work done on lenalidomide based nanoformulations.	21
	2.9.	Role of nanotechnology in treatment of glioma.	23
	2.10.	Role of mitochondria in cancer.	24
	2.10.1.	Warburg effect.	25
	2.10.2.	Mitochondrial dysfunction in glioma.	26
	2.10.3.	Considerations for mitochondrial targeting.	26
	2.11.	Polyethylenimine and its application in theranostic nanoparticles.	27
	2.12.	Iron oxide nanoparticles- A theranostic platform.	28
	2.12.1.	Methods of synthesis of iron oxide nanoparticles.	29
	2.12.1.1.	Coprecipitation method.	29
	2.12.1.2	Thermal decomposition (solvothermal method).	29
	2.12.1.3.	Sol-gel method.	29
	2.12.1.4.	Microemulsion method.	30
	2.12.1.5.	Hydrothermal method.	30
	2.12.1.6.	Polyol method.	30
	2.12.1.7.	Miscellaneous methods.	31
	2.12.2.	Applications of iron oxide nanoparticles in cancer treatment.	31
	2.12.2.1.	Photothermal therapy.	31
	2.12.2.2.	Magnetic hyperthermia.	31
	2.12.2.3.	Site specific drug delivery.	32
	2.12.2.4.	Magnetic resonance imaging contrast agents.	32
	2.12.3.	In vivo fate/Pharmacokinetics of iron oxide nanoparticles.	34
2.12.4.	Toxicological aspects of iron oxide nanoparticles.	34	
2.13.	References	36	
3. Analytical Method development.	3.1.	Materials.	40
	3.2.	Development of UV spectroscopic method for estimation of lenalidomide.	40
	3.2.1.	Equipments.	40
	3.2.2.	Preparation of Calibration curve.	40
	3.2.3.	Validation of analytical method for estimation of lenalidomide.	41

Chapter	Section	Title	Page no.
3. Analytical Method development.	3.2.3.1.	Linearity and Range.	41
	3.2.3.2.	Limit of detection (LOD) and Limit of quantification (LOQ).	42
	3.2.3.3.	Precision.	43
	3.2.3.4.	Accuracy.	43
	3.2.3.5.	Interference study/Specificity.	44
	3.3.	Estimation of lenalidomide in methanolic phosphate buffer saline pH 7.4 for in vitro drug release studies.	44
	3.3.1.	Equipments	45
	3.3.2.	Preparation of methanolic phosphate buffer saline pH 7.4.	45
	3.3.3.	Preparation of calibration curve.	45
	3.3.4.	Range and linearity.	46
	3.4.	Bioanalytical method for estimation of lenalidomide in plasma and brain.	46
	3.4.1.	Equipments.	46
	3.4.2.	Principle of the analytical method.	47
	3.4.3.	Preparation of standard samples in plasma and brain homogenate.	48
	3.5.	References	51
	4. Synthesis and Coating of nanoparticles.	4.1.	Materials.
4.2.		Screening of method for synthesis of Gadolinium doped Iron oxide nanoparticles (metallic core).	53
4.2.1.		Co-precipitation method.	53
4.2.1.1.		Procedure .	53
4.2.2.		Borohydride reduction.	54
4.2.2.1.		Procedure.	54
4.2.3.		Green synthesis (Tannin synthesis).	54
4.2.3.1.		Procedure.	54
4.2.4.		Determination of degradation temperature of precursors for solvothermal and polyol process.	55
4.2.5.		Solvothermal method.	55
4.2.5.1.		Procedure.	55
4.2.6.		Polyol method.	56
4.2.6.1.		Procedure.	56
4.3.		Comparison of all the methods and optimization of screened method for synthesis of metallic core.	58
4.4.		Synthesis of PEI analogues.	58
4.4.1.		Procedure.	58

Chapter	Section	Title	Page no.
4. Synthesis and Coating of nanoparticles.	4.5.	Characterization of PEI analogues.	59
	4.5.1.	Infrared spectroscopy.	59
	4.5.2.	Florescamine assay.	59
	4.6.	Carboxylation of metallic core.	60
	4.7.	Coating of drug on the metallic core and optimization.	60
	4.8.	Secondary PEI coating on drug coated core.	61
	4.9.	Results and discussion.	61
	4.9.1.	Screening of method for synthesis of Gadolinium doped iron oxide nanoparticles (metallic core).	61
	4.9.2.	Determination of degradation temperature of precursors for solvothermal and polyol process.	63
	4.9.3.	Solvothermal method.	64
	4.9.4.	Polyol method.	65
	4.9.5.	Comparison of all methods for synthesis of metallic nanoparticles.	66
	4.9.6.	Optimization of Polyol method for synthesis of metallic core.	67
	4.9.7.	Characterization of PEI analogues.	68
	4.9.7.1.	Infrared spectroscopy.	68
	4.9.7.2.	Florescamine assay.	69
	4.9.8.	Drug coating on core and its optimization.	70
4.10.	References.	72	
5. In vitro characterization of nanoparticles.	5.1.	Characterization of Gadolinium doped iron oxide nanoparticles (metallic core).	74
	5.1.1.	Transmission electron microscopy (TEM).	74
	5.1.2.	Zeta Potential.	74
	5.1.3.	<i>In vitro</i> MRI contrast.	74
	5.1.4.	Energy dispersive X- ray diffraction (EDAX).	75
	5.1.5.	X-ray diffraction (XRD).	76
	5.1.6.	Vibrating sample magnetometry (VSM).	76
	5.1.7.	<i>In vitro</i> hyperthermia.	76
	5.2.	Characterization of theranostic nanoparticles.	76
	5.2.1.	Differential scanning calorimetry (DSC).	76

Chapter	Section	Title	Page no.
5. In vitro characterization of nanoparticles.	5.2.2.	Particle size and zeta potential.	76
	5.2.3.	Transmission electron microscopy (TEM).	77
	5.2.4.	% Entrapment efficiency.	77
	5.2.5.	Gas chromatography.	77
	5.2.6.	<i>In vitro</i> drug release.	77
	5.2.7.	Stability study.	78
	5.3.	Results and discussion.	78
	5.3.1.	Characterization of Gadolinium doped iron oxide nanoparticles (metallic core).	78
	5.3.1.1.	Transmission electron microscopy.	78
	5.3.1.2.	Zeta potential.	79
	5.3.1.3.	In vitro MRI contrast.	79
	5.3.1.2.	Energy dispersive X- ray diffraction (EDAX).	80
	5.3.1.3.	X-ray diffraction (XRD).	81
	5.3.1.4.	Vibrating sample magnetometry (VSM).	83
	5.3.1.5.	In vitro hyperthermia.	84
	5.3.2.	Characterization of theranostic nanoparticles.	85
	5.3.2.1.	Differential scanning calorimetry (DSC).	85
	5.3.2.2.	Particle size and zeta potential.	86
	5.3.2.3.	Transmission electron microscopy (TEM).	87
	5.3.2.4.	% Entrapment efficiency.	87
	5.3.2.5.	Gas chromatography.	87
	5.3.2.6.	<i>In vitro</i> drug release.	88
5.3.2.7.	Stability study.	91	
5.4.	References	93	
6. Cell line and toxicity studies	6.1.	Materials.	97
	6.1.	Procurement and subculture of cell lines.	97
	6.2.	In vitro cytotoxicity (MTT assay).	98
	6.3.	Cell migration assay (Scratch assay).	99
	6.4.	Confocal microscopy.	99
	6.5.	Mitochondrial membrane potential (TMRM) and ATP levels.	100
	6.6.	PI staining.	100
	6.7.	Mucosal toxicity study.	100

Chapter	Section	Title	Page no.
6. Cell line and toxicity studies	6.8.	Hemolytic toxicity.	100
	6.9.	Results and discussions.	101
	6.9.1.	MTT assay.	101
	6.9.2.	Cell migration assay (scratch assay).	103
	6.9.3.	Confocal microscopy.	104
	6.9.4.	Mitochondrial membrane potential (TMRM) and ATP levels.	106
	6.9.5.	PI staining.	108
	6.9.6.	Mucosal toxicity study.	108
	6.9.7.	Hemolytic toxicity.	109
	6.10.	References.	111
7. <i>In vivo</i> biodistribution	7.1.	Materials.	113
	7.2.	Protocol for <i>in vivo</i> biodistribution studies.	113
	7.3.	Dose calculation for biodistribution.	113
	7.4.	Radiolabelling of theranostic nanoparticles.	114
	7.5.	Results and discussion.	114
	7.5.1.	Intranasal administration.	114
	7.5.2.	Intravenous administration.	115
	7.5.3.	Comparative analysis	116
	7.6.	References.	119
8. Summary and Conclusion	8.1.	Summary.	120
	8.1.1.	Introduction.	120
	8.1.2.	Fabrication and characterisation of magnetic metallic core.	121
	8.1.3.	Modification of PEI.	122
	8.1.4.	Fabrication and characterization of theranostic nanoparticles.	122
	8.1.5.	Cell line and toxicity studies.	123
	8.1.6.	<i>In vivo</i> biodistribution.	123
	8.2.	Conclusion.	124